NASDAQ:PBM Psyence Biomedical Q2 2025 Earnings Report $4.27 +0.05 (+1.18%) Closing price 08/25/2026 04:00 PM EasternExtended Trading$4.35 +0.08 (+1.87%) As of 08/25/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Psyence Biomedical EPS ResultsActual EPS$25.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APsyence Biomedical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APsyence Biomedical Announcement DetailsQuarterQ2 2025Date1/23/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Psyence Biomedical Earnings HeadlinesPsyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine DevelopmentAugust 19, 2026 | finanznachrichten.dePsyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine DevelopmentAugust 18, 2026 | finance.yahoo.comA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move. | Awesomely (Ad)Psyence BioMed Welcomes White House Support for Accelerated U.S. Ibogaine DevelopmentAugust 18, 2026 | quiverquant.comQPsyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine DevelopmentAugust 18, 2026 | globenewswire.comPsyence BioMed to Engage U.S. Stakeholders on Psychedelic Medicine Research and Ibogaine Supply InitiativesMay 15, 2026 | quiverquant.comQSee More Psyence Biomedical Headlines About Psyence BiomedicalPsyence Biomedical (NASDAQ:PBM) engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.View Psyence Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DICK's Sporting Goods Faces Pain Now for a Bigger PrizeStoneX: Too Far Too Fast?Pathward’s Credit Scare Tests Its Comeback StoryNVIDIA Earnings Could Move These 3 AI Stocks—Here’s What to WatchBeyond Big Tech: 3 Non-Tech Earnings Winners to WatchThe Bull Case for D-Wave After a Disappointing Earnings SeasonVisa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Upcoming Earnings Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
